EPISODE · Jun 9, 2026 · 2 MIN
From Terminal to Chronic: 7-Year Follow-Up Data from the CROWN Study
from TheBrief.Health · host TheBrief.Health
This review examines 7-year CROWN trial data showing lorlatinib’s unprecedented durability in ALK-positive NSCLC, highlighting survival gains, CNS protection, resistance suppression, and toxicity management.
What this episode covers
This review examines 7-year CROWN trial data showing lorlatinib’s unprecedented durability in ALK-positive NSCLC, highlighting survival gains, CNS protection, resistance suppression, and toxicity management.
NOW PLAYING
From Terminal to Chronic: 7-Year Follow-Up Data from the CROWN Study
No transcript for this episode yet
Similar Episodes
Apr 21, 2026 ·13m
Apr 19, 2026 ·16m
Apr 17, 2026 ·13m
Apr 13, 2026 ·11m
Apr 11, 2026 ·16m